• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

摩洛哥人群中的肢端肥大症。

Acromegaly among a Moroccan population.

作者信息

Guerboub Ahmed Anass, Issouani Jad, Joumas Kesly Jeny, Er Rahali Yassine

机构信息

Endocrinology Department, Mohammed V Military Academic Hospital, Faculty of Medicine and Pharmacy, Mohammed V-Souissi University, Rabat, Morocco.

出版信息

Pan Afr Med J. 2023 Dec 27;46:116. doi: 10.11604/pamj.2023.46.116.41952. eCollection 2023.

DOI:10.11604/pamj.2023.46.116.41952
PMID:38465009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10924612/
Abstract

Acromegaly is defined as an acquired dysmorphytic syndrome due to excessive secretion of growth hormone (GH) and consequently of insulin-like growth factor-1 (IGF-1). This is a retrospective study of patients who were hospitalized in the Endocrinology Department of the Mohammed V Military Academic Hospital in Rabat over a period of 14 years (2008 to 2022), reporting on their clinical, paraclinical and evolutionary profiles and comparing the results with the data in the literature. Nineteen patients were included in our study. The mean age was 42.7 ± 11.6 years, with a male predominance. The clinical manifestations were dominated by a dysmorphic syndrome present in 97.4% of cases, followed by complications related to acromegaly in 88.9% of cases. The diagnosis was made when GH and IGF-1 values were elevated in 88.9% and 93.8% of cases, respectively; with a mean GH value of 25.1 μg/L. Magnetic resonance imaging (MRI) was used to diagnose the location of pituitary adenoma in all cases, 78.9% of which were macroadenomas and 21.1% microadenomas. The majority of patients (78.9%) had recourse to transsphenoidal surgery. Medical treatment was carried out in 89.5% of cases. Postoperative radiotherapy was performed in 33% of cases. Disease control was achieved in 30.1% of cases. This study shows the complex management of acromegaly. Disease control is a necessary condition in order to avoid complications, but is often difficult to obtain.

摘要

肢端肥大症被定义为一种由于生长激素(GH)过度分泌以及随之而来的胰岛素样生长因子-1(IGF-1)过度分泌导致的后天性畸形综合征。这是一项对在拉巴特穆罕默德五世军事学术医院内分泌科住院14年(2008年至2022年)的患者进行的回顾性研究,报告了他们的临床、辅助检查和病情演变情况,并将结果与文献数据进行比较。我们的研究纳入了19名患者。平均年龄为42.7±11.6岁,男性占主导。临床表现以97.4%的病例出现畸形综合征为主,其次是88.9%的病例出现与肢端肥大症相关的并发症。分别在88.9%和93.8%的病例中,当GH和IGF-1值升高时做出诊断;平均GH值为25.1μg/L。所有病例均使用磁共振成像(MRI)诊断垂体腺瘤的位置,其中78.9%为大腺瘤,21.1%为微腺瘤。大多数患者(78.9%)接受了经蝶窦手术。89.5%的病例进行了药物治疗。33%的病例进行了术后放疗。30.1%的病例实现了疾病控制。这项研究表明了肢端肥大症的复杂管理。疾病控制是避免并发症的必要条件,但往往难以实现。

相似文献

1
Acromegaly among a Moroccan population.摩洛哥人群中的肢端肥大症。
Pan Afr Med J. 2023 Dec 27;46:116. doi: 10.11604/pamj.2023.46.116.41952. eCollection 2023.
2
Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.经鼻内镜蝶窦手术治疗肢端肥大症:214 例手术经验及根据当前共识标准的治愈率。
J Neurosurg. 2013 Dec;119(6):1467-77. doi: 10.3171/2013.8.JNS13224. Epub 2013 Sep 27.
3
Acromegaly.肢端肥大症
Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4.
4
Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.单纯内镜经蝶窦手术治疗肢端肥大症:垂体中心治疗 67 例的结果。
Neurosurg Focus. 2010 Oct;29(4):E7. doi: 10.3171/2010.7.FOCUS10167.
5
Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.内镜经蝶窦手术治疗肢端肥大症患者中肿瘤特征及术前术后激素水平对激素缓解的影响。
Neurosurg Focus. 2020 Jun;48(6):E10. doi: 10.3171/2020.3.FOCUS2080.
6
Assessment of long-term remission of acromegaly following surgery.肢端肥大症手术后长期缓解情况的评估。
J Neurosurg. 2003 Apr;98(4):719-24. doi: 10.3171/jns.2003.98.4.0719.
7
Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.术后 GH 和 IGF-1 降低程度可预测肢端肥大症术后激素缓解情况。
Front Endocrinol (Lausanne). 2021 Nov 18;12:743052. doi: 10.3389/fendo.2021.743052. eCollection 2021.
8
[Acromegaly].[肢端肥大症]
Presse Med. 2009 Jan;38(1):92-102. doi: 10.1016/j.lpm.2008.09.016. Epub 2008 Nov 11.
9
Secondary diabetes mellitus in acromegaly: Case report and literature review.肢端肥大症继发糖尿病:病例报告及文献复习。
Medicine (Baltimore). 2024 Sep 27;103(39):e39847. doi: 10.1097/MD.0000000000039847.
10
[Outcome of somatostatin analogue treatment in acromegaly].[生长抑素类似物治疗肢端肥大症的疗效]
Orv Hetil. 2009 Aug 2;150(31):1457-62. doi: 10.1556/OH.2009.28688.

引用本文的文献

1
Clinical Profile and Treatment Outcomes in Patient with Acromegaly Using 14 Acromegaly Consensus Criteria.采用14项肢端肥大症共识标准的肢端肥大症患者的临床概况及治疗结果
Indian J Endocrinol Metab. 2025 Mar-Apr;29(2):195-201. doi: 10.4103/ijem.ijem_522_24. Epub 2025 Apr 29.

本文引用的文献

1
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study.肢端肥大症的多维老年评估:一项比较性横断面研究。
BMC Geriatr. 2021 Oct 26;21(1):598. doi: 10.1186/s12877-021-02549-4.
2
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?肢端肥大症患者生长抑素受体亚型表达的差异:靶向治疗的新方向?
Hormones (Athens). 2022 Mar;21(1):79-89. doi: 10.1007/s42000-021-00327-w. Epub 2021 Oct 21.
3
Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.口服葡萄糖负荷后 IGF-1 和生长激素抑制的患者的临床和激素表现:一项回顾性队列研究。
Eur J Endocrinol. 2021 Jul 1;185(2):289-297. doi: 10.1530/EJE-21-0024.
4
The Biochemical Diagnosis of Acromegaly.肢端肥大症的生化诊断
J Clin Med. 2021 Mar 9;10(5):1147. doi: 10.3390/jcm10051147.
5
Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center.肢端肥大症的并发症和合并症-波兰中心的回顾性研究。
Front Endocrinol (Lausanne). 2021 Mar 16;12:642131. doi: 10.3389/fendo.2021.642131. eCollection 2021.
6
Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis.肢端肥大症患者症状和健康相关生活质量的改善:系统评价和荟萃分析。
J Clin Endocrinol Metab. 2021 Jan 23;106(2):577-587. doi: 10.1210/clinem/dgaa868.
7
A Pituitary Society update to acromegaly management guidelines.垂体学会关于肢端肥大症管理指南的更新。
Pituitary. 2021 Feb;24(1):1-13. doi: 10.1007/s11102-020-01091-7. Epub 2020 Oct 20.
8
Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly.长效奥曲肽(善龙®)术前治疗对肢端肥大症患者的疗效。
Endokrynol Pol. 2020;71(4):285-291. doi: 10.5603/EP.a2020.0050.
9
Clinical features and therapeutic outcomes of patients with acromegaly in Saudi Arabia: a retrospective analysis.沙特阿拉伯肢端肥大症患者的临床特征和治疗结果:回顾性分析。
Hormones (Athens). 2020 Sep;19(3):377-383. doi: 10.1007/s42000-020-00191-0. Epub 2020 May 9.
10
Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality.肢端肥大症的诊断延迟时间延长与发病率和死亡率的增加有关。
Eur J Endocrinol. 2020 Jun;182(6):523-531. doi: 10.1530/EJE-20-0019.